Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Stomach Neoplasms 12Neoplasms 8Breast Neoplasms 5Triple Negative Breast Neoplasms 4Neoplasm Metastasis 4Uterine Cervical Neoplasms 3Small Cell Lung Carcinoma 3Ovarian Neoplasms 3Osteosarcoma 3Cholangiocarcinoma 3Carcinoma, Non-Small-Cell Lung 3Squamous Cell Carcinoma of Head and Neck 2Recurrence 2Esophageal Squamous Cell Carcinoma 2Esophageal Neoplasms 2Drug-Related Side Effects and Adverse Reactions 2Colorectal Neoplasms 2Carcinoma, Hepatocellular 2Biliary Tract Neoplasms 2Advanced Solid Tumor 2Advanced Gastric Cancer 2Thyroid Neoplasms 1Solid Tumor, Adult 1Sarcoma 1Quality of Life 1Nasopharyngeal Neoplasms 1Nasopharyngeal Carcinoma 1Mouth Neoplasms 1Metastatic Castration Resistant Prostate Cancer 1Lymphoma, Large B-Cell, Diffuse 1

Interventions

enzalutamide 9Abiraterone Acetate 5rucaparib 2Prednisone 2Docetaxel 2pembrolizumab 1fluzoparib 1apatinib 1abiraterone 1Blood Specimen Collection 1Biopsy 1Androgen Antagonists 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Metastatic Castration Resistant Prostate Cancer × apatinib × Clear all
NCT04869488 2025-01-24

A Trial of SHR3162 Combined With Apatinib Mesylate Tablets or SHR3162 Monotherapy in Patients With Metastatic Castration Resistant Prostate Cancer

Jiangsu HengRui Medicine Co., Ltd.

Phase 2 Completed
93 enrolled
Genitourinary

Metastatic Castration Resistant Prostate Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡